Clinical Trial Detail

NCT ID NCT02643303
Title A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Ludwig Institute for Cancer Research
Indications

kidney cancer

melanoma

sarcoma

breast cancer

Advanced Solid Tumor

head and neck squamous cell carcinoma

Merkel cell carcinoma

urinary bladder cancer

cutaneous T cell lymphoma

Therapies

Durvalumab + Poly ICLC

Tremelimumab

Age Groups: adult

No variant requirements are available.